One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Publication number: 20130303494Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: July 19, 2013Publication date: November 14, 2013Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIESInventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130303561Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: ApplicationFiled: April 17, 2013Publication date: November 14, 2013Inventors: Michele Hummel, Donald J. Kyle, Nathan Lautermilch, Garth Whiteside
-
Publication number: 20130302418Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: ApplicationFiled: May 24, 2013Publication date: November 14, 2013Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred P. Tonelli
-
Patent number: 8580856Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.Type: GrantFiled: February 6, 2013Date of Patent: November 12, 2013Assignee: NcNeil-PPC, Inc.Inventors: Jim Swann, Peter Cummins
-
Patent number: 8580855Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.Type: GrantFiled: October 17, 2007Date of Patent: November 12, 2013Assignee: McNeil-PPC, Inc.Inventors: Jim Swann, Peter Cummins
-
Publication number: 20130296347Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.Type: ApplicationFiled: March 29, 2013Publication date: November 7, 2013Inventor: Roberto Ciccocioppo
-
Publication number: 20130295168Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: March 5, 2013Publication date: November 7, 2013Inventor: Durect Corporation
-
Publication number: 20130295170Abstract: Opiates, amphetamines, barbiturates and other drugs such as benzodiazepines are extensively abused or misused and are frequently the cause of death by overdosing. These drugs are also prone to oxidation and the final degradation products depend on the reactants and the reaction conditions. This invention describes the use of inactivating agents such as permanganates, peroxides, persulfates, bismuthates, periodates or other oxidants in a dosage form as an approach to minimize abuse and overdose. The product is designed such that the inactivating agent is released if there is an attempt to extract the drug from the formulation or in cases of overdose. Once released, the inactivating agent quickly degrades the drug and converts it into inactive compounds. Since the reactants (drug and inactivating agent) are incompatible in situations of normal drug usage, they are kept separated within the vehicle of the invention, but released for interaction in case of misuse.Type: ApplicationFiled: May 3, 2013Publication date: November 7, 2013Applicant: KYDES Pharmaceuticals LLCInventor: Stephen Dordunoo
-
Publication number: 20130295177Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: ApplicationFiled: May 23, 2013Publication date: November 7, 2013Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
-
Patent number: 8574552Abstract: Disclosed is a pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, said composition comprising i) an effective amount of a narcotic active ingredient, and ii) a pharmaceutically acceptable amine having a pK of about 8 or greater, wherein the molar ratio of amine:active ingredient is at least about 5:1.Type: GrantFiled: July 21, 2006Date of Patent: November 5, 2013Assignee: Alpex Pharma S.A.Inventors: Federico Stroppolo, Shahbaz Ardalan
-
Publication number: 20130289059Abstract: The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood.Type: ApplicationFiled: April 10, 2013Publication date: October 31, 2013Inventor: Eric T. Fossel
-
Publication number: 20130289061Abstract: Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS stimulant in the subject. Also disclosed is a method of reducing or preventing the development of addiction to a CNS stimulant in a subject, comprising, administering the CNS stimulant and administering a mu opioid receptor antagonist to thereby reduce or prevent the development of addiction to the CNS stimulant in the subject. Also disclosed are pharmaceutical compositions comprising a central nervous system stimulant and an opioid receptor antagonist. Examples of central nervous system stimulants (such as methylphenidate) and opioid receptor antagonists (such as naltrexone) are provided.Type: ApplicationFiled: June 24, 2013Publication date: October 31, 2013Inventors: Pradeep G. Bhide, Jinmin Zhu, Thomas J. Spencer, Joseph Biederman
-
Publication number: 20130289062Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.Type: ApplicationFiled: June 25, 2013Publication date: October 31, 2013Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
-
Publication number: 20130287845Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: March 5, 2013Publication date: October 31, 2013Inventors: Su Il Yum, Grant Schoenhard, Arthur J. Tipton, John W. Gibson, John C. Middleton
-
Publication number: 20130289060Abstract: Compounds of formula: in which R4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.Type: ApplicationFiled: October 19, 2011Publication date: October 31, 2013Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Gavril Pasternak, Susruta Majumdar
-
Publication number: 20130287849Abstract: Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Inventors: Christine Andersen, Karsten Lindhardt, Jan Martin Oevergaard, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Pernille Kristine Hoeyrup Hemmingsen
-
Publication number: 20130287850Abstract: Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.Type: ApplicationFiled: June 26, 2013Publication date: October 31, 2013Inventors: Christine Andersen, Karsten Lindhardt, Jan Martin Oevergaard, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Pernille Kristine Hoeyrup Hemmingsen
-
Patent number: 8569329Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.Type: GrantFiled: August 17, 2011Date of Patent: October 29, 2013Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
-
Patent number: 8569330Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.Type: GrantFiled: December 28, 2011Date of Patent: October 29, 2013Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
-
Publication number: 20130281388Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:Type: ApplicationFiled: December 17, 2012Publication date: October 24, 2013Inventor: Alkermes Pharma Ireland Limited
-
Publication number: 20130281479Abstract: The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.Type: ApplicationFiled: October 15, 2012Publication date: October 24, 2013Applicant: Abbott LaboratoriesInventor: Abbott Laboratories
-
Publication number: 20130280323Abstract: Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed.Type: ApplicationFiled: April 12, 2013Publication date: October 24, 2013Inventors: Qi Fang, Don A. Archibald, Madhu Sudan Hariharan, Roger E. Gordon
-
Publication number: 20130281481Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: ApplicationFiled: June 21, 2013Publication date: October 24, 2013Applicant: RECKITT BENCKISER HEALTHCARE (UK) LIMITEDInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, B. Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Publication number: 20130281480Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.Type: ApplicationFiled: March 5, 2013Publication date: October 24, 2013Inventor: Durect Corporation
-
Publication number: 20130280176Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight water-soluble polymer, at least one polyglycol, at least one polysaccharide, at least one clay mineral, and, optionally, an effervescent system.Type: ApplicationFiled: April 18, 2013Publication date: October 24, 2013Applicant: Mallinckrodt LLCInventors: Thomas A. Diezi, Jae Han Park, Siva N. Raman
-
Patent number: 8563038Abstract: Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be employed to produce pharmaceutical compositions, such as controlled release dosage forms, adjusted to a specific administration scheme.Type: GrantFiled: June 24, 2010Date of Patent: October 22, 2013Assignee: Egalet Ltd.Inventors: Christine Andersen, Karsten Lindhardt, Jan Martin Oevergaard, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Pernille Kristine Hoeyrup Hemmingsen
-
Patent number: 8563571Abstract: The present invention is directed to crystalline forms of oxymorphone hydrochloride.Type: GrantFiled: July 21, 2011Date of Patent: October 22, 2013Assignee: Noramco, Inc.Inventors: Karen S. Gushurst, Leonard J. Chyall, Lien H. Koztecki, Brenton Skylar Wolfe
-
Publication number: 20130273159Abstract: Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.Type: ApplicationFiled: April 23, 2012Publication date: October 17, 2013Inventors: William Wayne Howard, Russell Francis Somma
-
Publication number: 20130273152Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable shell containing a drug of abuse within an oil comprising physiologically tolerable unsaturated fatty acids.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes
-
Publication number: 20130273162Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapuetic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.Type: ApplicationFiled: April 12, 2012Publication date: October 17, 2013Inventor: Michael Hsin Chwen LI
-
Publication number: 20130273153Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.Type: ApplicationFiled: June 22, 2011Publication date: October 17, 2013Inventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal K. Gupta, Stephen Overholt
-
Publication number: 20130274280Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes, Magnus N. Hattrem
-
Publication number: 20130267502Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Gregory A. Demopulos, George A. Gaitanaris, Roberto Ciccocioppo
-
Publication number: 20130266651Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Inventors: Robert J. Edwards, Jr., Chih-Ting Huang, Nam-Mew Pul
-
Patent number: 8551520Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: December 20, 2012Date of Patent: October 8, 2013Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred Tonelli
-
Patent number: 8552025Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.Type: GrantFiled: December 16, 2009Date of Patent: October 8, 2013Assignee: Progenics Pharmaceuticals, Inc.Inventors: Suketu P. Sanghvi, Thomas A. Boyd
-
Patent number: 8551986Abstract: In general, the invention provides methods and compositions for treating sequela of weight gain or pain insensitivity, e.g., in a subject suffering from a psychiatric disorder, such as schizophrenia. The combinations employed in the invention include a second generation antipsychotic agent and an opioid receptor antagonist.Type: GrantFiled: December 7, 2006Date of Patent: October 8, 2013Assignee: The McLean Hospital CorporationInventors: Igor Elman, David Borsook, Jan Wasley
-
Publication number: 20130261145Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130259940Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: October 3, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130259909Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: ApplicationFiled: May 7, 2013Publication date: October 3, 2013Applicant: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Publication number: 20130261144Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Applicants: Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20130259941Abstract: Dosage forms having a core having a surface having means for controlling release(s) on an active agent(s); methods of manufacturing, tools used in manufacturing; and uses of the dosage forms are described.Type: ApplicationFiled: December 12, 2011Publication date: October 3, 2013Applicant: PURDUE PHARMA L.P.Inventor: Edward O'Donnell
-
Publication number: 20130259939Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: October 3, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130259938Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: October 3, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130261143Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: February 12, 2013Publication date: October 3, 2013Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 8546418Abstract: The present invention provides a compound of formula I: wherein R1, R2, R2? and X? are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.Type: GrantFiled: March 28, 2008Date of Patent: October 1, 2013Assignees: Progenics Pharmaceuticals, Inc., Wyeth, LLCInventors: Alfred A. Avey, Appavu Chandrasekaren, Harold D. Doshan, Julio Perez, Yakov Rotshteyn
-
Publication number: 20130252994Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: ApplicationFiled: May 7, 2013Publication date: September 26, 2013Applicant: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Publication number: 20130251643Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
-
Publication number: 20130251796Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Publication number: 20130251802Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Applicant: Purdue Pharma L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang